ClinicalTrials.gg
CompletedNCT01849497Updated Nov 29, 2018Results posted

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

A Phase 3 interventional study of Evolocumab Pre-filled Syringe and Evolocumab AI/pen in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Amgen. Completed at 26 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-11-29.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing evolocumab in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. evolocumab · Hypercholesterolemia.

Enrollment
26th of 36
149 · median 308
Started
2013
with 10 others
Phase 3
22 of 36
none open now
Registered
15th of 36
by date
Lead sponsor
30 of 36
Amgen

Among the 36 studies testing evolocumab in Hypercholesterolemia, this one is the 26th largest by enrollment, is one of 11 that started in 2013, is one of 22 in phase 3, and was the 15th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 36 studies testing evolocumab in Hypercholesterolemia is open now. Recruiting first, the newest first:

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing evolocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Keywords

  • LDL-C, triglycerides, high cholesterol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Fasting LDL-C at screening > 85 mg/dL
  • Fasting triglycerides less than or equal to 400 mg/dL (4.5 mmol/L) Exclusion Criteria:
  • (NYHA) III or IV heart failure
  • Uncontrolled cardiac arrhythmia
  • Uncontrolled hypertension
  • Type 1 diabetes or poorly controlled type 2 diabetes
  • Uncontrolled hypothyroidism or hyperthyroidism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Evolocumab PFS

    Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.

    Biological: Evolocumab Pre-filled Syringe

  • Experimental
    Evolocumab AI/pen

    Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.

    Biological: Evolocumab AI/pen

Interventions

  • Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.

    Also known as: AMG 145, Repatha

  • BiologicalEvolocumab AI/pen

    Drug page: Evolocumab

    Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.

    Also known as: AMG 145, Repatha

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4

    Self-administration of evolocumab was assessed by a telephone interview at Weeks 2 and 4. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all.

    Time frame: Week 2 and Week 4

Secondary outcomes

  1. Percent Change From Baseline in LDL-C at Week 6

    Time frame: Baseline and Week 6

07

Results

Posted Oct 9, 2015

Participant flow

Eligible patients were men and women ≥ 18 and ≤ 80 years of age with fasting low-density lipoprotein cholesterol (LDL-C) ≥ 85 mg/dL, fasting triglycerides ≤ 400 mg/dL and on a stable dose of a statin with or without ezetimibe for at least 4 weeks. The first patient enrolled on 18 April 2013 and last patient enrolled on 05 August 2013.

Participant flow — Overall Study
MilestoneEvolocumab PFSEvolocumab AI/Pen
Started7574
Received treatment7574
Completed7470
Not completed14
Withdrew: Withdrawal by subject12
Withdrew: Sponsor decision01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4

Self-administration of evolocumab was assessed by a telephone interview at Weeks 2 and 4. Each participant was asked about all attempted injection(s) and if the injection was administered in part, full, or none at all.

Time frame:
Week 2 and Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4
percentage of participantsEvolocumab PFSEvolocumab AI/Pen
Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 496.0 (88.9 to 98.6)89.2 (80.1 to 94.4)
Statistical analysis
  • Evolocumab PFS vs Evolocumab AI/Pen · Treatment difference: -6.8 · 95% CI -16.3 to 2.0
SecondaryPercent Change From Baseline in LDL-C at Week 6
Time frame:
Baseline and Week 6
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 6
percent changeEvolocumab PFSEvolocumab AI/Pen
Percent Change From Baseline in LDL-C at Week 6-59.74 ± 2.57-63.43 ± 2.67
Statistical analysis
  • Evolocumab PFS vs Evolocumab AI/Pen · Ls mean treatment difference: -3.70 · 95% CI -10.38 to 2.99

Adverse events

Collected over From first dose of study drug until 28 days after last study drug administration (up to 8 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Evolocumab PFS—3/75 (4%)4/75 (5.3%)
Evolocumab AI/Pen—2/74 (2.7%)2/74 (2.7%)
Most frequent serious events
Most frequent serious events
EventEvolocumab PFSEvolocumab AI/Pen
Cerebrovascular accidentNervous system disorders0/751/74
Glomerulonephritis minimal lesionRenal and urinary disorders0/751/74
Gastrooesophageal reflux diseaseGastrointestinal disorders1/750/74
CholecystitisHepatobiliary disorders1/750/74
CholelithiasisHepatobiliary disorders1/750/74
AsthmaRespiratory, thoracic and mediastinal disorders1/750/74
Most frequent other events
Most frequent other events
EventEvolocumab PFSEvolocumab AI/Pen
HeadacheNervous system disorders4/752/74

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of study drug).

Age, Continuous
Age, Continuous(years)Evolocumab PFSEvolocumab AI/PenTotal
Mean61.2 ± 11.160.6 ± 9.660.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Evolocumab PFSEvolocumab AI/PenTotal
Female362662
Male394887
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Evolocumab PFSEvolocumab AI/PenTotal
American Indian or Alaska Native000
Asian279
Black or African American11718
Native Hawaiian or Other Pacific Islander011
White6258120
Missing011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Evolocumab PFSEvolocumab AI/PenTotal
Hispanic or Latino9615
Not Hispanic or Latino6668134
Stratification Factor: LDL-C Level
Stratification Factor: LDL-C Level(participants)Evolocumab PFSEvolocumab AI/PenTotal
< 130 mg/dL5656112
≥ 130 mg/dL191837
LDL-C Concentration
LDL-C Concentration(mg/dL)Evolocumab PFSEvolocumab AI/PenTotal
Mean116.9 ± 25.0118.1 ± 28.7117.5 ± 26.8
08

Study locations

26 sites
  • Research Site
    Encino, California 91436, United States
  • Research Site
    Thousand Oaks, California 91360, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Westlake Village, California 91361, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Atlanta, Georgia 30328, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Hammond, Indiana 46320, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Manlius, New York 13104, United States
  • Research Site
    Syracuse, New York 13210, United States
  • Research Site
    Cadiz, Ohio 43907, United States
  • Research Site
    Marion, Ohio 43302, United States
  • Research Site
    Hillsboro, Oregon 97123, United States
  • Research Site
    Duncansville, Pennsylvania 16635, United States
  • Research Site
    Lansdale, Pennsylvania 19446, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    London, Ontario N5W 6A2, Canada
  • Research Site
    Toronto, Ontario M8V 3X8, Canada
  • Research Site
    Toronto, Ontario M9V 4B4, Canada
  • Research Site
    Woodstock, Ontario N4S 5P5, Canada
  • Research Site
    Pointe-Claire, Quebec H9R 3J1, Canada
09

References and documents

Publications

  • Boccara F, Dent R, Ruilope L, Valensi P. Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia. Adv Ther. 2017 Aug;34(8):1876-1896. doi: 10.1007/s12325-017-0586-8. Epub 2017 Jul 17. PubMed 28717862 ↗
  • Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent R, Djedjos C, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators. Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies. Circulation. 2017 May 9;135(19):1819-1831. doi: 10.1161/CIRCULATIONAHA.116.025233. Epub 2017 Mar 1. PubMed 28249876 ↗
  • Kasichayanula S, Grover A, Emery MG, Gibbs MA, Somaratne R, Wasserman SM, Gibbs JP. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769-779. doi: 10.1007/s40262-017-0620-7. PubMed 29353350 ↗
  • Dent R, Joshi R, Stephen Djedjos C, Legg J, Elliott M, Geller M, Meyer D, Somaratne R, Recknor C, Weiss R. Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting. Springerplus. 2016 Mar 9;5:300. doi: 10.1186/s40064-016-1892-3. eCollection 2016. PubMed 27066336 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Sep 2013, 4 months.

Results were first posted in Oct 2015, 2 years 1 month after primary completion. A results delay was requested in May 2014.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 4 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2013
First posted
May 8, 2013
StartActual
Apr 18, 2013
Primary completionActual
Sep 2, 2013
Results delay requested
May 2, 2014
Results first posted
Oct 9, 2015
Last update
Nov 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01849497
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 8, 2013
Start date
Apr 18, 2013
Primary completion
Sep 2, 2013
Results posted
Oct 9, 2015
Last update
Nov 29, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion